Treatments, such as renin–angiotensin–aldosterone system blockade in patients with Alport syndrome22 and tolvaptan in autosomal dominant polycystic kidney disease patients with PKD1 or PKD2 gene findings, can delay progression to kidney failure.26,27 Furthermore, positive genetic findings can help physicians confirm the need for such treatments. This evidence concerns the gene REN and kidney failure.